SC 13G/A: CytoMed Therapeutics Ltd

AI Summary

SC 13G/A filing by CytoMed Therapeutics Ltd.

Risk Assessment

Risk Level: low

FAQ

Filing Documents

• formsc13ga.htm (SC 13G/A) — 104KB
• 0001493152-24-021087.txt ( ) — 105KB

From the Filing

SC 13G/A 1 formsc13ga.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CytoMed Therapeutics Limited Ordinary Shares, of no par value per share Y1R80M106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). SCHEDULE 13G CUSIP No. Y1R80M106 1 Names of Reporting Persons Choo Chee Kong 2 Check the appropriate box if a member of a Group (see instructions) (a) (b) 3 Sec Use Only 4 Citizenship or Place of Organization: Republic of Singapore Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power : 3,066,575 Ordinary Shares (1) (2) (3) 6 Shared Voting Power : -0- 7 Sole Dispositive Power : 3,066,575 Ordinary Shares (1) (2) (3) 8 Shared Dispositive Power : -0- 9 Aggregate Amount Beneficially Owned by Each Reporting Person: 3,066,575 Ordinary Shares (1) (2) (3) 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) 11 Percent of class represented by amount in row (9): 26.57% (4) 12 Type of Reporting Person (See Instructions): IN (1) Consists of 2,468,560 Ordinary Shares held by Glorious Finance Limited (“Glorious Finance”). Mr. Choo Chee Kong owns 55.0% of shares in Glorious Finance. Mr. Choo Chee Kong is deemed to beneficially own 55.0% of the 4,488,291 Ordinary Shares held by Glorious Finance. Mr. Choo Chee Kong disclaims beneficial ownership of the remaining shares held by Glorious Finance to the extent that he does not have an economic interest therein. The aforementioned Ordinary Shares were issued in exchange for capital contributions to the Issuer. (2) Consists of 410,515 Ordinary Shares held by EP Capital Inc. (“EP Capital”). Mr. Choo Chee Kong is deemed to beneficially own the 410,515 Ordinary Shares held by EP Capital. The aforementioned Ordinary Shares were contributed to EP Capital by Glorious Finance, Wang Shu and Zeng Jieming, each a founding shareholder of the Issuer and each of whom acquired their respective Ordinary Shares in exchange for capital contributions to the Issuer. (3) Consists of 187,500 Ordinary Shares held directly by Mr. Choo Chee Kong. The aforementioned Ordinary Shares were acquired by Mr. Choo Chee Kong with personal funds. (4) Based on 11,540,000 Ordinary Shares of CytoMed Therapeutics Limited (the “Company”) outstanding as of May 21, 2024. 2 SCHEDULE 13G CUSIP No. Y1R80M106 1 Names of Reporting Persons Glorious Finance Limited 2 Check the appropriate box if a member of a Group (see instructions) (a) (b) 3 Sec Use Only 4 Citizenship or Place of Organization: British Virgin Islands Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power : 4,488,291 Ordinary Shares 6 Shared Voting Power : -0- 7 Sole Dispositive Power : 4,488,291 Ordinary Shares 8 Shared Dispositive Power : -0- 9 Aggregate Amount Beneficially Owned by Each Reporting Person: 4,488,291 Ordinary Shares 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) 11 Percent of class represented by amount in row (9): 38.89% (1) 12 Type of Reporting Person (See Instructions): CO (1) Based on 11,540,000 Ordinary Shares of the Company outstanding as of May 21, 2024. 3 Item 1. (a) Name of Issuer: CytoMed Therapeutics Limited (b) Address of Issuer’s Principal Executive Offices: 1 Commonwealth Lane #08-22, Singapore 149544 Item 2. (a) Name of Person Filing: Choo Chee Kong Glorious Finance Ltd. (b) Address of Principal Business Office or, if None, Residence: Choo Chee Kong: CytoMed Therapeutics Limited, 1 Commonwealth Lane #08-22, Singapore 149544 Glorious Finance Ltd.: Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola VG1110 British Virgin Islands (c) Citizenship/Place of Organisation: Choo Chee Kong: Singapore Glorious Finance Ltd.: British Virgin Islands (d) Title and Class of Securities: Ordinary Shares, no par value per share (e) CUSIP No.: Y1R80M106 4 Item 3. If this statement is filed pursuant to §§ 240.13

View Full Filing

View this SC 13G/A filing on SEC EDGAR